for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Moderna Announces First Participant Dosed In Nih-Led Phase 1 Study Of Mrna Vaccine Against Novel Coronavirus

March 16 (Reuters) - Moderna Inc:

* MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN NIH-LED PHASE 1 STUDY OF MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS

* MODERNA - PREPARING FOR POTENTIAL PHASE 2 STUDY UNDER ITS OWN IND TO BUILD ON DATA FROM ONGOING PHASE 1 STUDY OF VACCINE AGAINST NOVEL CORONAVIRUS

* MODERNA INC - MANUFACTURE OF MRNA-1273 MATERIAL FOR POTENTIAL PHASE 2 TRIAL, WHICH COULD BEGIN IN A FEW MONTHS, IS UNDERWAY Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up